Leaders in Pharmaceutical Business Intelligence (LPBI) Group

PLENARY KEYNOTE PRESENTATIONS: WEDNESDAY, APRIL 30 | 8:00 – 9:45 AM @ BioIT World, April 29 – May 1, 2014 Seaport World Trade Center, Boston, MA

 

Reporter: Aviva Lev-Ari, PhD, RN

 

Keynote Introduction: Sponsored by Sanjay Joshi, CTO, Life Sciences, EMC Isilon

 

Stephen H. Friend, M.D., Ph.D.

President, Co-Founder and Director of Sage Bionetworks

 

Dr. Friend is the President of Sage Bionetworks. He was previously Senior Vice President and Franchise Head for Oncology Research at Merck & Co., Inc. where he led Merck’s Basic Cancer Research efforts. He led the Advanced Technologies and Oncology groups to firmly establish molecular profiling activities throughout Merck’s laboratories around the world, as well as to coordinate oncology programs from Basic Research through phase IIA clinical trials. Prior to joining Merck, Dr. Friend along with Dr. Leland Hartwell founded and co-led the Fred Hutchinson Cancer Research Center’s “Seattle Project”, an advanced institute for drug discovery. While there Drs. Friend and Hartwell developed a method for examining large patterns of genes that led them to co-found Rosetta Inpharmatics in 1997. Dr. Friend has also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. He received his B.A. in philosophy, his Ph.D. in chemistry and his M.D. from Indiana University. Dr. Friend was named an Ashoka Fellow for his work at Sage Bionetworks.

From the FLOOR OF THE AMPHITHEATRE @ BioIT – 4/30 8AM EST –

NOW!!!!!!!!

STEVE FRIEND

NextGen Biomedical Research – collaborative Team Approaches

Open Knowledge like currency – exchange

Scientists are in time of transition, symptoms of disease

Scale of Complexity – Regulation of signaling by wild-type and oncogenic Ras PATHWAY

• expression profiles – classifies, different views of the disease
• activation of RAS
• overlapping Pathways: same protein has a differnt function: TGFR
• the rules are still unknown

Hypothesis Driven Biomedical Research – extrapulation from particular to general, embrace multiple particulars

adjacent “TRUES”

six new tools:

1. generate “omics data – new possibility

2. simultaneously represent protein using NETWORKS

3. cloud computing

4. data and analysis is to be uncoupled, diffeerent parties

5. chronology: Patients contribut to research – top medications, Top Diets, Top supplements

6. open social media, allows citizens and experts to use gaming

Sagebase.org

TOOL:

1. technology platform – common scientific knowledge – git-hub

Synapse -GBM.annotated.whitelist.maf -Provenance – who did what, why, what came out

TCGA Pan-Cancer Project = The Cancer Genome Atlas

Analysis of: 12 Tumor types

Performed by 150 researchersform 30 institutions

2. NIA: Industry & Academia on Altzheimers’ Disease

Takeda, GSK, Mayo clinic, University – every quarter show and share

3. AML Treatment Federation – Fimm, OHSU, Fred Hutchinson Cancer, Pheonix Children’s Hospital

MULTIPLE EXPERT working simuntaneously

4. Structure of a Challenge

• crowdsourcing
• data and methods of measurement
• IBM-Sage-DREAM Breast Cancer Prognosis Challenge #1
• person who perform, get to write and credit of a paper
• DREAM8 Challenges: Participants numbers going up

Purpose of Challenges:

• use to build a community who trust, scientist who do not known each other can share competition and collaboration
• Career changer – Challenges is a career builder

DREAM 8.5 computational challenge – ACCURACY not speed, computational efficiency

“Somatic Mutation Calling (SMC)” – UC Santa Cruz

SMC structure 239 registrants 309 entries to date

Global optimization od SMC variant identification

External Organizer

Phenotypic vs genotypic data – bring patients to collaborate with researches on Health Tracking

– Patients as a Sources of Billable Proccedured

A Complete Medical Information COmmons

Goal: BRIDGE, citizens, Scientists, MDs – current initiatives

• Parkinson
• Sleep quality by sleep approved drugs
• Breast cancer

Study participant and Study researcher close the loop.

Architecture Summary

• Study design
• questions
• combining open tools –>> put on Synapse –>> build the structure of Challenge

The Resilience Project – next month on TED, lack power for fully treat – Power of Diagnosis

—>>>>>>>Project childhood disease: accelerate drug discover, individuals

Existin Expert & Emerging Experts

continuity between nacant technology and current Research practices

 

NEEDED skill for collaboration – not taught. Scienstts mustit be in the best interest to improve annotation so others can use their output

Self interest of a Research – that other will be interested

Bring on board: NIH, Wellcome Trust, Gates Foundation